TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: local injection-site reactions (erythema and hematoma/bleeding)
Endpoint domain: Adverse events/effects
Primary endpoint: death or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: target-lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of leaving rooms and calling out
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to quiet each night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent satisfaction and treatment acceptability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: short birth interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: C‐peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of major/clinically relevant non-major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Effect sizes in CMD-SQ subscales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effect sizes in SF-36 subscales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severity of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of entering a care home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Survival rate of blastocysts
Endpoint domain: Mortality/survival
Primary endpoint: Clinical pregnancies achieved
Endpoint domain: Mortality/survival
Primary endpoint: Live births achieved
Endpoint domain: Mortality/survival
Primary endpoint: muscle function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum urinary flow rate improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) during active stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sympathetic HR rebound post-stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Premature Ejaculation Diagnostic Tool (PEDT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioequivalence in terms of rate and extent of absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment failure (PCR corrected)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of atomoxetine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole PTH (wPTH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Ca and P metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean test score for nurses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of achieving azoospermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Regularity of gastric slow waves in the fed state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of bradygastria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of tachygastria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: metronidazole absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metronidazole clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child negative affect at 26 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GB AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: formoterol AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in attention, concentration and working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in work quality subscale of the work behavior inventory
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Progression to colectomy
Endpoint domain: Mortality/survival
Primary endpoint: Symptomatic and corticosteroid use outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of regular menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment failure rates for SUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mesh erosion probability
Endpoint domain: Adverse events/effects
Primary endpoint: Circulating adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean leucine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma clearance of vecuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate constant for drug equilibration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of the concentration-response relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: observed communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Alteration of autonomic cardiovascular control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VCAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Albumin-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: school attendance and/or part-time employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean %HRR-AR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean %HRR-CV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall success rate at 30 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incomplete ablation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: local tumor control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinically significant weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to first analgesic administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cumulative doses of meperidine over 24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean doses of diclofenac over 24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S(I) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: S(G) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiorespiratory fitness (VO2 peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of reintubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen Desaturation Index (ODI) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HF-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: isoFEF(25-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma LPS concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: level of HCO3‐ post FLESHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: adverse effects during hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: tramadol requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total cholesterol (TC) level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL-C (low-density-lipoprotein cholesterol) level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of major clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Favorable functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS of overall pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with moderate-to-severe pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Levels of serum TC, TG, LDL-C, and HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Burning sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy of techniques in ISD group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toleration time during cold-pressor task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort and relaxation levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Constant-Murley Score (CMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health outcomes in T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the Fugl-Meyer Assessment (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitric Oxide (NO) production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival advantage for women in heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Risk of hospitalization for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Women's worries about the health of the baby
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General anxiety and depressive symptoms during pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative anaesthetic complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: BICRO‐39 total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self organisation subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: psychological wellbeing subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tremor score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bradykinesia score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rigidity score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Willingness to pay (WTP) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal inspiratory pressure improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal expiratory pressure improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharyngeal swallowing security signs improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Morphological quality of blastocysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placement torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resonance frequency values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symmetry of gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPO, NO, and CAT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical results of open reduction and internal fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic results of open reduction and internal fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-recurrence survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients reaching therapeutic range INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean INR values at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients overcorrected (INR<2)
Endpoint domain: Adverse events/effects
Primary endpoint: Major response (CR/PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cognitive function score (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: composite cardiovascular outcome
Endpoint domain: Mortality/survival
Primary endpoint: subsequent revascularizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean body surface temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fibrinogen level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom bother
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time expenditure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients not requiring steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial inflow impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Venous congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Obstructive lung disease diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vocal cord dysfunction diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Positive diagnosis from Methacholine challenge testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relief of diarrhoeal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in coronary artery diameter in response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in coronary blood flow in response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Lp-PLA2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-Cog 11-item total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean treatment duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean change of thickness of the sternocleidomastoid tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine withdrawal symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: night-time blood pressure reducing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ameliorating quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response rate based on HAM-A score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep quality improvements
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: general satisfaction with information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with treatment decision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: dyspnea scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving BP control with the initial starting dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor side effects
Endpoint domain: Adverse events/effects
Primary endpoint: VISA-A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hypoglycemic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protection rates for poliovirus types 1, 2, and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometry mean titers (GMT) for poliovirus types 1, 2, and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean microleakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spreader penetration depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower clinical events after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysmenorrhea recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale score for dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of recurrent cases requiring further surgical or hormone treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bone mineral density rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Newly formed immature bone rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean rate of gain of lumbar BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of skin self-examination (SSE) with photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Specificity of skin self-examination (SSE) with photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite endpoint (death, myocardial infarction, bypass surgery, recurrent ischemia, repeat angioplasty/stent insertion)
Endpoint domain: Mortality/survival
Primary endpoint: Median intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-Terminal-proBNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart/mediastinum ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased fatigue at D28
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Increase in knowledge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cPOS rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) of femoral neck and lumbar vertebrae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum beta‐CTX levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum SOST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Platelet aggregation on ADP test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second attempt success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean time to intubate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increasing signal in brain areas related to depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Remission status after six ECTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient radiation dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of clinically significant cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes